Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1

Assay and Drug Development Technologies

Volumn 5, Issue 6, 2007, Pages 723-735

  Sharlow, Elizabeth R ^a,b   Leimgruber, Stephanie ^b   Shun, Tong Ying ^b   Lazo, John S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; CYCLIC AMP DEPENDENT PROTEIN KINASE; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE 12; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; POLO LIKE KINASE 1; POLO LIKE KINASE 1 INHIBITOR; PROTEIN KINASE D; PROTEIN KINASE INHIBITOR; RHO KINASE; UNCLASSIFIED DRUG;

ARTICLE; AUTOANALYSIS; DRUG DETERMINATION; DRUG IDENTIFICATION; ENZYME INHIBITOR INTERACTION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; IC 50; RELIABILITY; VALIDATION PROCESS;

BLOTTING, WESTERN; CELL CYCLE PROTEINS; DATA INTERPRETATION, STATISTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROMETRY; FREEZING; HYDROGEN-ION CONCENTRATION; INDICATORS AND REAGENTS; KINETICS; MINIATURIZATION; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; SILVER STAINING; SUBSTRATE SPECIFICITY; TEMPERATURE;

EID: 38049018111     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2007.102     Document Type: Article

References (51)

1. Barr F, Silljé HH, Nigg E: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5:429-440.
2. Golsteyn R, Schultz S, Bartek J, Ziemiecki A, Ried T, Nigg E: Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994;107:1509-1517.
3. Golsteyn R, Mundt K, Fry A, Nigg E: Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle formation. J Cell Biol 1995;129:1617-1628.
4. Toyoshima-Morimoto F, Taniguchi E, Nishida E: Plk1 promotes nuclear translocation of human cdc25C during prophase. EMBO J 2002;3:341-348.
5. β-TrCP. Proc Natl Acad Sci U S A 2004;101:4419-4424.
6. Lowery D, Clauser K, Hjerrild M, Lim D, Alexander J, Kishi K, et al.: Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 2007;26:2262-2273.
7. Matsumura S, Toyoshima F, Nishida E: Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1. J Biol Chem 2007;282:15217-15227.
8. Baumann C, Körner R, Hofmann K, Nigg E: PICH, a centrosome- associates SNF2 family ATPase, is regulated by Plk1 and required for spindle checkpoint. Cell 2007;128:101-114.
9. Simizu S, Okada H: Mutations in PLK gene lead to instability of PLK protein in human tumour cell lines. Nat Cell Biol 2000;2:852-854.
10. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, et al.: Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004;60:240-245.
11. Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhasu P, et al.: Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005;5:259-265.
12. Takai A, Hamanaka R, Yoshimatsu J, Miyakawa I: Polo-like kinases (PLKs) and cancer. Oncogene 2005;24:287-291.
13. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Jochen Stutte H, et al.: Prognostic significance of polo-like kinase (PLK) in non-small cell lung cancer. Oncogene 1997;14:543-549.
14. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, et al.: Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005;446:442-450.
15. Knecht R, Oberhauser C, Strebhardt K: PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000;89:535-536.
16. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K: Prognostic significance of Polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:2794-2797.
17. Strebhardt K, Ullrich A: Targeting polo-like kinase I for cancer therapy. Nat Cancer Rev 2006;6:321-330.
18. Smith M, Wilson M, Hamanaka R, Chase D, Kung H, Longo D, et al.: Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophy Res Commun 1997;234:397-405.
19. Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K: Effect of RNA silencing of Polo-like kinase 1 (Plk1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002;94:1863-1877.
20. Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmüller M, et al.: Downregulation of human pololike kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002;21:3162-3171.
21. Spänkuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K: Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against Plk1. J Natl Cancer Inst 2004;96:862-872.
22. Guan R, Tapang P, Leverson J, Albert D, Giranda V, Luo Y: Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53 defective oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65:2698-2704.
23. Kappel S, Matthess Y, Zimmer B, Kaufmann M, Strebhardt K: Tumor inhibition by genomically integrated inducible RNAi-cassettes. Nucleic Acids Res 2006;34:4527-4536.
24. Wada M, Kawahito Y, Kimura S, Kohno M, Ishino H, Kimura M, et al.: siRNA targeting PLK1 induces apoptosis of synoviocytes in rheumatoid arthritis. Biochem Biophys Res Commun 2007;357:353-359.
25. Harris P, Zhu X, Pamies C, Rottkamp C, Ghabari H, McShea A, et al.: Neuronal polo-like kinase in Alzheimer disease indicates cell cycle change. Neurobiol Aging 2000;21:837-841.
26. Patel D, Incassati A, Wang N, McCance D: Human papillomavirus type 16 E6 and E7 cause polyploidy in human keratinocytes and up-regulation of G2/M phase proteins. Cancer Res 2004;64:1299-1306.
27. Bostik P, Dodd G, Villinger F, Mayne A, Ansari A: Dysregulation of the Polo-like kinase pathway in CD4+ T cells is characteristic of pathogenesis simian immunodeficiency virus infection. J Virol 2004;78:1464-1472.
28. Gallina A, Simoncini L, Garbelli S, Percivalle E, Pedrali-Noy G, Lee K, et al.: Polo-like kinase 1 as a target for human cytomegalovirus pp65 lower matrix protein. J Virol 1999;73:1468-1478.
29. Liu Y, Shreder K, Gai W, Corral S, Ferris D, Rosenblum JS: Wortmannin, a widely used phophoinositide 3-kinase inhibitor, also potently inhibits mammalian Polo-like kinase. Chem Biol 2005;12:99-107.
30. Walker E, Pacold M, Perisic O, Stephens L, Hawkins P, Wymann M, et al.: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine. Mol Cell 2000;6:909-919.
31. McInnes C, Mezna M, Fischer P: Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 2005;5:181-197.
32. Goh K, Wang H, Yu N, Zhou Y, Zheng Y, Lim Z, et al.: Plk1 as a potential drug target in cancer therapy. Drug Dev Res 2004;62:349-361.
33. Stevenson C, Capper E, Roshak A, Marquez B, Eichman C, Jackson J, et al.: The identification and characterization of the marine natural product scytonenim as a novel antiproliferative pharmacophores. J Pharmacol Exp Ther 2002;303:858-866.
34. McInnes C, Mazumdar A, Mezna M, Meades C, Midgley C, Scaerou F, et al.: Inhibitors of polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2006;2:608-617.
35. Gumireddy K, Reddy M, Cosenza S, Nathan R, Baker S, Papathi N, et al.: ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7:275-286.
36. Qunitas-Cardama A, Kantarjian H, Cortes J: Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834-848.
37. Munzert G, Steinbild, Frost A, Hedborn S, Rentschler J, Kaiser R, et al.: A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 to patients with advanced solid tumors. J Clin Oncol 2006;24(18 Suppl):3069.
38. Steegmaier M, Hoffmann M, Baum A, Lénart P, Petronczki M, Krssák M, et al.: BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-322.
39. Lénart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp J, Hoffmann M, et al.: The small molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304-315.
40. Gaudet EA, Huang K, Zhang Y, Huang W, Mark D, Sportsman JR: A homogenous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J Biomol Screen 2003;8:164-175.
41. Sportsman JR, Gaudet EA, Boge A: Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening. Assay Drug Dev Technol 2004;2;205-214.
42. Boge A: TR-FRET detection with IMAP. IMAP application note number 7. http://www.moleculardevices.com/ home/html (accessed October 30, 2007).
43. IMAP TR-FRET Progressive Binding Systems. http:// www.moleculardevices. com/home/html (accessed October 25, 2007).
44. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ, Johannes FJ: Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase C isoenzymes. FEBS Lett 1996;392:77-80.
45. Kothe M, Kohls D, Low S, Coli R, Cheng A, Jacques S, et al.: Structure of the catalytic domain of human polo-like kinase 1. Biochemistry 2007;46:5960-5971.
46. Klumpp M, Boettcher A, Becker D, Meder G, Blank J, Leder L, et al.: Readout technologies for highly miniaturized kinase assays applicable to high throughput screening in a 1536-well format. J Biomol Screen 2006;11:617-633.
47. Loomans EEMG, van Doornmalen AM, Wat JWY, Zaman GJR: High throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogenous assay for protein kinases. Assay Drug Devel Technol 2003;1:445-453.
48. Lu Z, Yin Z, James L, Syto R, Stafford J, Koseoglu S, et al.: Development of fluorescence polarization beadbased coupled assay to target different activity/conformation states of a protein kinase. J Biomol Screen 2004;9:309-321.
49. Turek-Etienne TC, Kober T, Stafford J, Bryant R: Development of a fluorescence polarization AKT serine/threonine kinase assay using an immobilized metal ion affinity-based technology. Assay Drug Devel Technol 2003;1:545-553.
50. Brisson Tierno M, Johnston P, Foster C, Skoko J, Shinde S, Shun T, et al.: Development and optimization of high throughput in vitro protein phosphatase screening assays. Nat Protocols 2007;2:1134-1144.
51. AID 797. http://pubmed.ncbi.nlm.nih.gov (accessed October 30, 2007).